Global Active Pharmaceutical Ingredients (APIs) Market will be US$ 261.3 Billion by 2027, Due to Rising Geriatric Population, Ongoing Research on Numerous Novel, Ground-Breaking Products
20 Jan, 2023

According to Renub Research's latest report, "Global Active Pharmaceutical Ingredients (API) Market, Size, forecast 2023-2027, Industry Trends, Share, Growth, Company Analysis," the Global API (Active Pharmaceutical Ingredients) Market will reach US$ 261.30 Billion by 2027. A biologically active ingredient in a pharmaceutical drug (tablet, capsule, cream, injectable) capable of producing the required effects on the body for treating a medical condition. APIs can create a more feasible healthcare system by introducing more innovative products. Oncology, cardiology, CNS and neurology, orthopaedics, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology are some diseases that use high-quality drugs where APIs find their application.

According to Renub Research, the Global API Industry will grow at a CAGR of 6.52% during the forecast period.

The growth in active pharmaceutical ingredients (API) can be credited to the advancements in manufacturing facilities and the increasing prevalence of chronic diseases, such as Cancer and Cardiovascular diseases. Also, favorable government policies for API production, accompanied by changes in geopolitical situations, are propelling market growth.

The global elderly population is on the rise. The process of aging affects the immune system and weakens it. Growing older also increases the patient's susceptibility to acquiring infectious diseases and enhances the chances of getting other diseases, such as diabetes and CVD. The 65 and above-aged population was expected to rise from 962 million in 2018 to 2.1 billion by 2050, as per the UN 2018. 

Large molecule segment is growing due to its complex composition:

More than 90% of drugs in the market are small molecules, but large molecules, also known as biologics, are rapidly gaining popularity and significance. The reason for this popularity is the complex composition of the large molecules. They are composed of 1,300 amino acids, similar to human proteins. Additionally, biologics demonstrate encouraging results in the chosen drug therapy with fewer side effects.   

Generic APIs are predicted to hold the largest market share by 2027:

The rise in patent expiration of branded drugs is the most crucial element pushing the growth of this market. In addition, the growing prevalence of diabetes, chronic diseases, and cardiovascular diseases are also expected to drive the general development of the market. Moreover, the current government reimbursement programs have supported lower-cost options, which will additionally expand the generic APIs market growth rate in the future. Also, the immense number of licensing and partnering strategies to launch new products by major vendors are expected to create profitable opportunities for the market.

High investments are surging the growth of Biotech APIs:

The increase in the requirement for biopharmaceuticals and the higher competence of these molecules has driven the segment's growth. Furthermore, the broadening of the biotech segment can be credited to increased investments in the biotechnology and biopharmaceutical sectors. This permits the innovation of new molecules that help treat diseases like cancer. According to WHO, cardiovascular diseases count for the deaths of 17.9 million people yearly, accompanied by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). The synthetic API segment held the largest revenue share. The reason for this is the greater availability of raw materials and uncomplicated agreements for the composition of these molecules. 

Captive APIs have supremacy in the market share:

Owing to the trouble-free availability of raw materials and substantial investments by major competitors to develop high-end manufacturing facilities, the captive API market will have its supremacy in the market share. Furthermore, recent developments and initiatives by key players suggest that they are highly focused on in-house manufacturing over outsourcing.

Oncology Application category is predicted to grow at a steady rate:

Changing lifestyles and the rise in the number of cancer cases are the factors that are aiding the growth of the market. The rising adoption of a desk-bound lifestyle is driving the increase of various metabolic disorders. Hormonal imbalance is an alarming concern in most countries. In addition, the surge in hormone-dependent aging problems also provides for the oncology application's growth.

Asia-Pacific is predicted to exhibit the fastest growth rate based on region:

The Asia-Pacific market growth is driven by the rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, a growing trend of outsourcing, and an increase in the elderly population. Moreover, rising investments and funding by eminent sellers in product potentialities and business expansion is expected to fuel the market.

Competitive Landscape:

The key competitors who are dealing in active pharmaceutical ingredients (API) are; Sanofi SA, F. Hoffman-La Roche Ltd., Pfizer, Inc., Abbott Laboratories, Bayer, Merck &Co., BoehringerIngelheim GmbH, GlaxoSmithKline Plc., Novartis, Eli Lilly Company, and Teva Pharmaceuticals.

Market Summary:

• Molecule - the Report covers the Global Active Pharmaceutical Ingredients Market by molecule in 2 viewpoints (small molecule and large molecule).
• Type - By type, the report covers the Active Pharmaceutical Ingredients market from 2 viewpoints (Innovative and Generic).
• Synthetic - Global Active Pharmaceutical Ingredients Market breakup into two viewpoints (Biotech and Synthetic).
• Manufacturer Type - By manufacturer type, Global Active Pharmaceutical Ingredients Market break up into two viewpoints (Captive and Merchant).
• Application - Global Active Pharmaceutical Ingredients Market breaks up into six viewpoints (cardiology, oncology, CNS and neurology, orthopedic, endocrinology, and others).
• Region - Renub Research report covers by region in 5 viewpoints (North America, Europe, Asia-Pacific, Latin America, and Middle-East and Africa).
• Key Players - All the major players have been covered from 4 Viewpoints (Overview, Strategy, Merger/Acquisition, and Financial Insights) Sanofi SA, F. Hoffman-La Roche Ltd., Pfizer, Inc., Abbott Laboratories, Bayer, Merck &Co., BoehringerIngelheim GmbH, GlaxoSmithKline Plc., Novartis, Eli Lilly Company, and Teva Pharmaceuticals.